We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Compendia Bioscience Announces Commercial Release and Availability of Oncomine™ Concepts Map
Product News

Compendia Bioscience Announces Commercial Release and Availability of Oncomine™ Concepts Map

Compendia Bioscience Announces Commercial Release and Availability of Oncomine™ Concepts Map
Product News

Compendia Bioscience Announces Commercial Release and Availability of Oncomine™ Concepts Map


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Compendia Bioscience Announces Commercial Release and Availability of Oncomine™ Concepts Map"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Compendia Bioscience, Inc. has announced the release and immediate availability of Oncomine™ Concepts Map, a high-value product extension of Compendia’s flagship product Oncomine™ Professional.

Oncomine Concepts Map (OCM) combines nearly 7,000 Oncomine cancer gene signatures with 11,000 gene, protein, drug, and pathway signatures collected from the literature and other public sources.

The technology uses gene sets as a common language to compare and link disparate biological concepts, as recently described in the journal Neoplasia. A second study published in Nature Genetics used Oncomine Concepts Map to analyze prostate cancer gene expression in the context of the other gene signatures available in OCM. The result was an important new model describing the progression of prostate cancer.

The Company says that three major biotech and pharmaceutical companies have already committed to licensing Oncomine Concepts Map on top of their existing Oncomine licenses, and many additional companies are actively evaluating the technology.

Advertisement